Salbutamol vs Levosalbutamol: What the Enantiomer Evidence Actually Shows

Levosalbutamol costs more than salbutamol, is marketed as the cleaner version of the same drug, and has been the subject of a twenty-year argument that most summaries settle far too quickly in one direction or the other. The chemistry behind the claim is real. Whether it produces a difference a patient would notice is a separate question, and the answer depends heavily on which trials you read.

This is the evidence on both sides, including the parts that do not favour the more expensive option.

The chemistry, and why anyone bothered

Salbutamol, called albuterol in the United States, is a chiral molecule. It has been sold for decades as a racemic mixture, meaning equal parts of two mirror-image forms: (R)-salbutamol and (S)-salbutamol.

Beta-2 agonist activity resides almost exclusively in the (R)-enantiomer (PMID: 11236808). The (S)-enantiomer has minimal binding affinity for the beta-2 receptor, which means half of every dose of standard salbutamol is not doing the job the drug was prescribed for (PMID: 16872269).

Levosalbutamol, sold as levalbuterol in the United States, is purified (R)-salbutamol with the (S) form removed. The commercial argument was straightforward: give the active half only, at half the milligram dose.

The case against the (S) isomer

If (S)-salbutamol were simply inert, this would be a rounding error rather than a debate. The argument for levosalbutamol is that it is not inert.

Reviews of the pharmacology describe evidence that (S)-salbutamol opposes the desirable effects of (R)-salbutamol within the racemic mixture, and contributes to features characteristic of asthma including airway obstruction and bronchial hyperresponsiveness (PMID: 16872269). A separate review reported that during regular use of racemic salbutamol there is a progressive decline in protective efficacy and a corresponding intensification of airway responsiveness, and that this decline is largely absent during regular use of (R)-salbutamol (PMID: 15991945).

That claim, if it holds, is about regular use rather than a single dose, which is an important qualification. It says little about the reliever taken twice a month and rather more about the reliever taken several times a day.

Why the (S) isomer builds up

The pharmacokinetics explain how a supposedly inactive half could matter at all. Salbutamol is metabolised almost exclusively by the enzyme sulfotransferase 1A3 into an inactive metabolite. (R)-salbutamol is metabolised by that route up to 12 times faster than (S)-salbutamol (PMID: 11236808).

The consequence is that after a dose of racemic salbutamol, the active (R) form clears quickly while the (S) form lingers at relatively higher plasma concentrations. With repeated dosing, the ratio in the body shifts steadily away from the therapeutic form. This is the mechanistic backbone of the whole levosalbutamol argument, and it is not disputed.

What is disputed is whether the accumulated (S) form does enough harm at clinical doses to justify the price difference.

What the head-to-head trials found

Three comparative studies with usable numbers.

A randomised double-blind study in 60 children aged 5 to 18 presenting with acute asthma exacerbation gave three nebulisations at 20-minute intervals in the first hour. The levosalbutamol group showed significant increases in oxygen saturation and peak expiratory flow with reduced tachypnoea and asthma score, and no significant change in heart rate or serum potassium. The racemic salbutamol group also improved clinically, but with significant tachycardia and a fall in potassium (PMID: 20012785).

A later randomised double-blind trial in children aged 5 to 15 with acute exacerbation reported the following after treatment (PMID: 36594293):

Measure after treatment	Levosalbutamol	Racemic salbutamol
Respiratory rate (per minute)	24.4 (SD 5.6)	27.6 (SD 5.3)
Heart rate (per minute)	115.5 (SD 16.4)	124.5 (SD 12.0)
Oxygen saturation in room air	97.2% (SD 1.8)	95.0% (SD 1.6)
Peak expiratory flow (L/min)	159.6 (SD 30.7)	143.8 (SD 27.1)

All four differences reached statistical significance at p below 0.05, and the authors again reported significant tachycardia with racemic salbutamol.

A randomised open parallel study in 60 adults with mild persistent asthma over four weeks reported significantly greater reduction with levosalbutamol in shortness of breath (P less than 0.001), chest tightness (P=0.033), wheeze (P=0.01), cough (P=0.024) and overall symptom score (P less than 0.001), with better quality of life scores and greater percentage reversibility in FEV1 (P=0.034), forced vital capacity (P=0.029) and peak flow (P=0.0003) (PMID: 22144765).

The counterweight, stated plainly

Read only the paragraphs above and levosalbutamol looks clearly better. That would be a selective reading, and anyone selling the drug has an obvious incentive to stop there. Four qualifications belong alongside those results.

The trials are small. Sixty patients per study, single centre. Small trials produce larger apparent effect sizes than large ones, consistently and predictably, and several of the differences reported here are the kind that shrink when the sample grows.

One key study was open-label. In the four-week adult study, both patients and assessors knew which drug was being given, and the primary outcomes were symptom scores and quality of life questionnaires, which are exactly the outcomes most sensitive to knowing what you are taking.

A large review reached a more measured conclusion. A review of levosalbutamol reported that its pharmacodynamic and pharmacokinetic profiles were similar to those of racemic salbutamol with no additional effects, that levosalbutamol 0.625 mg was at least as effective as racemic salbutamol 2.5 mg, and that it was bronchoprotective after methacholine challenge (PMID: 18031154). At least as effective at a quarter of the milligram dose is a real finding. It is not the same as superior.

Major asthma guidelines do not recommend levosalbutamol in preference to salbutamol. Guideline committees reviewing the full body of evidence, including the larger trials, have not concluded that the enantiomer difference produces a clinically important advantage that justifies the additional cost. That is the position a prescriber is most likely to take, and it is not an unreasonable one.

The doses are not interchangeable

This trips people up when switching products. Levosalbutamol is dosed at a lower milligram figure because it contains only the active isomer, so the numbers on the two boxes are not comparable.

Form	Salbutamol	Levosalbutamol
Metered dose inhaler, per actuation	100 mcg	50 mcg
Dry powder capsule	200 mcg	100 mcg
Nebuliser solution, common strengths	2.5 mg	0.31 mg, 0.63 mg, 1.25 mg

The reported clinical study equivalence is levosalbutamol 0.625 mg being at least as effective as racemic salbutamol 2.5 mg (PMID: 18031154). Nebulising a 2.5 mg-equivalent quantity of levosalbutamol because that is the number a patient remembers from the old prescription is a dosing error, not a cautious substitution.

What we stock, and what it costs

Product	Molecule	Strength	Form	Price
Asthalin Inhaler	Salbutamol	100 mcg	Metered dose inhaler	$10.00
Asthalin Rotacaps	Salbutamol	200 mcg	Dry powder capsule	$10.00
Asthalin Respules	Salbutamol	2.5 mg	Nebuliser respule	$19.00
Levolin Synchrobreathe	Levosalbutamol	50 mcg	Breath-actuated inhaler	$18.00
Levolin Inhaler	Levosalbutamol	50 mcg	Metered dose inhaler	$27.50
Levolin 0.63 mg Respules	Levosalbutamol	0.63 mg	Nebuliser respule	$13.00
Levolin 1.25 mg Respules	Levosalbutamol	1.25 mg	Nebuliser respule	$15.00

The price gap at inhaler level is meaningful in percentage terms and small in absolute terms. At respule level the two are close enough that cost is not the deciding factor for most people.

Side effects: the same list, argued over the size

Both drugs produce the same class effects, because both act on the same receptor. Tremor, palpitations, headache, nervousness and muscle cramp are the common ones. At higher or repeated doses, tachycardia and a fall in serum potassium follow, which is the pharmacology of beta-2 stimulation rather than a defect in any particular product (PMID: 36430683).

The specific claim for levosalbutamol is a smaller cardiac and metabolic burden at equivalent bronchodilation, and this is where the two paediatric exacerbation trials are most interesting, because heart rate and potassium are objective measurements not open to reporting bias. Both studies reported significant tachycardia with racemic salbutamol and not with levosalbutamol (PMID: 20012785, PMID: 36594293). Those were repeated nebulised doses within one hour, which is the highest-exposure scenario in routine practice and the one where a difference would be most likely to appear.

A note on the tablets. Oral salbutamol, sold as Asthalin 2 mg and Asthalin 4 mg, and oral levosalbutamol as Levolin 1 mg and Levolin 2 mg, deliver the drug systemically. That means more tremor and more cardiac effect for less airway effect than an inhaled dose. Inhaled delivery is preferred for asthma in every major guideline, and oral beta agonists are a fallback rather than a convenience upgrade.

Levosalbutamol with ipratropium

A common combination pairs levosalbutamol with ipratropium bromide, an anticholinergic bronchodilator that works through a separate mechanism. We stock it as Duolin Inhaler, Duolin Respules and Duolin Rotacaps.

The rationale is additive bronchodilation from two receptor systems, which is well established in acute severe asthma and in chronic obstructive pulmonary disease. Ipratropium carries its own effects, chiefly dry mouth and, if the spray reaches the eyes, blurred vision and pupil dilation, so a mouthpiece rather than a loose mask matters when nebulising.

The decision that matters more than this one

Salbutamol against levosalbutamol is a comparison between two relievers, and it is not the most consequential decision in this treatment area.

The Global Initiative for Asthma no longer recommends short-acting beta agonist monotherapy at any step of asthma treatment, and names as-needed inhaled corticosteroid with formoterol as preferred reliever therapy for adults and adolescents with mild asthma (PMID: 38237858). Someone managing asthma on a reliever alone, whichever isomer it contains, is on a regimen that guidelines moved away from years ago.

A patient using two or three reliever canisters a year is telling you something about their control, not about their choice of reliever. The productive response is a controller inhaler, which is covered in our guide to budesonide with formoterol, or a review of the oral controller option in our guide to montelukast. The asthma treatment overview sets out how the pieces fit.

A straight recommendation

For most adults using a reliever occasionally, salbutamol is the sensible default. It is cheaper, it has the longer safety record, guidelines treat the two as equivalent options, and the theoretical disadvantage of the (S) isomer is built on regular heavy use rather than intermittent use.

Levosalbutamol has a stronger case in two situations. First, patients who get marked tremor or palpitations on salbutamol at doses they need, where the objective heart rate findings in the comparative trials are directly relevant. Second, children needing repeated nebulised doses, which is the setting where both double-blind trials found differences.

What neither option addresses is the reason a reliever is being reached for often. That is a controller question, and it belongs with a prescriber.

Medical disclaimer

This article is educational and does not replace advice from a qualified healthcare professional. Salbutamol and levosalbutamol require a prescription in the United States, United Kingdom, Canada and Australia. The trial results quoted describe specific study populations under specific conditions and cannot be applied directly to any individual. Doses of the two drugs are not interchangeable milligram for milligram. Worsening asthma, or a reliever inhaler that is no longer relieving symptoms, needs urgent medical assessment rather than repeated dosing.

References

• Boulton DW, Fawcett JP. The pharmacokinetics of levosalbutamol: what are the clinical implications? PubMed PMID: 11236808.
• Levosalbutamol in the treatment of asthma. PubMed PMID: 16872269.
• Levalbuterol hydrochloride. PubMed PMID: 15991945.
• Levosalbutamol. Review of pharmacodynamics, pharmacokinetics and comparative efficacy. PubMed PMID: 18031154.
• Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma. PubMed PMID: 20012785.
• Comparative efficacy of levosalbutamol and racemic salbutamol in the treatment of acute exacerbation of asthma. PubMed PMID: 36594293.
• Racemic salbutamol and levosalbutamol in mild persistent asthma: a comparative study of efficacy and safety. PubMed PMID: 22144765.
• Salbutamol in the management of asthma: a review. PubMed PMID: 36430683.
• The role of ICS-containing rescue therapy versus SABA alone in asthma management today. PubMed PMID: 38237858.

Related reading on asthma treatment

Relievers are only half the picture. See our guides to budesonide with formoterol inhalers and maintenance and reliever therapy and montelukast side effects and the FDA boxed warning. The full range of inhalers, respules and tablets is on our asthma and respiratory medicines page.